Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement.
Illumina Inc. and Oxford Nanopore Technologies Ltd. announced a strategic alliance including a commercialization agreement and equity investment. Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE(TM) Technology products developed by Oxford Nanopore for DNA sequencing into the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales. As part of the agreement, Illumina made an equity investment of $18.0 million, which will be used to accelerate the development of BASETM Technology. Illumina has also agreed to make an additional equity investment upon the achievement of a specific technical milestone.
